InvestorsHub Logo
Followers 30
Posts 2777
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Friday, 04/08/2022 3:04:20 PM

Friday, April 08, 2022 3:04:20 PM

Post# of 721
The company has received positive feedback from the FDA on both its potency assay matrix and its proprietary cell co-culture assay. Based on this response, they expect to request a pre-BLA meeting in July and to complete a BLA submission for lifileucel by August. In addition, plan to open a PhIII trial for lifileucel in combination with pembro for the treatment of immune checkpoint inhibitor naïve front-line metastatic melanoma in late 2022.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IOVA News